Johnson & Johnson To Co-Promote Cephalon's ADHD Treatment Modafinil
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal allows J&J to opt out if its own attention deficit/hyperactivity disorder therapy Concerta loses exclusivity.
You may also be interested in...
Cephalon Sparlon For ADHD To Get Psychopharm Committee Review
The March 23 review of the new indication for modafinil, currently marketed as Provigil for narcolepsy, will likely focus on safety differences compared to other ADHD drugs.
Cephalon Sparlon For ADHD To Get Psychopharm Committee Review
The March 23 review of the new indication for modafinil, currently marketed as Provigil for narcolepsy, will likely focus on safety differences compared to other ADHD drugs.
Cephalon Expects To Launch Modafinil For ADHD In Early 2006
The company must resolve final Sparlon labeling issues identified in an “approvable” letter.